Salesforce.com’s ride in the cloud has hit a speed bump. Company shares were down 4% in after-hours trading Wednesday after the enterprise software company’s fiscal Q4 2015 EPS and revenue outlook missed Wall Street views, as did its fiscal 2016 sales guidance. Salesforce (CRM), however, beat views with its EPS and sales for its fiscal Q3 ended Oct. 31. The conservative guidance, particularly for 2016, could be the company being
What’s coming down the road? Cars as robots, more or less. The L.A. Auto Show kicked off Tuesday with press days focused on the technology of the “connected car,” which will eventually help lead to self-driving cars, like those that Google (GOOGL) and recent auto-tech IPO Mobileye (MBLY) have been working on. Volvo, for one, showcased in a news conference Tuesday that, like Google, its cars can drive themselves now — following
Generic and specialty drugmaker Actavis agreed to acquire Allergan for more than $66 billion on Monday, potentially creating a pharmaceutical giant with $23 billion in annual sales and a market cap around $147 billion. Actavis (ACT) will pay $129.22 plus 0.3683 Actavis share for each share of Allergan (AGN). That’s equal to $220.54 based on Monday’s closing price. It is appreciably above the hostile bid that Valeant Pharmaceuticals